Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer
After the successful development of targeted therapy and immunotherapy for the treatment of advanced-stage non-small cell lung cancer (NSCLC), these innovative treatment options are rapidly being applied in the adjuvant setting for early-stage NSCLC. Some adjuvants that have recently been approved include osimertinib for epidermal growth factor receptor-mutated tumors and atezolizumab and pembrolizumab for selected patients with resectable NSCLC. Numerous studies on various targeted therapies and immunotherapy with or without chemotherapy are currently ongoing in the adjuvant setting. However, several questions regarding optimal strategies for adjuvant treatment remain unanswered. The present review summarizes the available literature, focusing on recent advances and ongoing trials with targeted therapy and immunotherapy in the adjuvant treatment of early-stage NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
Tuberculosis and respiratory diseases - 87(2024), 1 vom: 15. Jan., Seite 31-39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Mi-Hyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carcinoma, Non-Small-Cell Lung |
|---|
| Anmerkungen: |
Date Revised 03.01.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4046/trd.2023.0085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364591463 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364591463 | ||
| 003 | DE-627 | ||
| 005 | 20240108141246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4046/trd.2023.0085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM364591463 | ||
| 035 | |a (NLM)37967564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Mi-Hyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a After the successful development of targeted therapy and immunotherapy for the treatment of advanced-stage non-small cell lung cancer (NSCLC), these innovative treatment options are rapidly being applied in the adjuvant setting for early-stage NSCLC. Some adjuvants that have recently been approved include osimertinib for epidermal growth factor receptor-mutated tumors and atezolizumab and pembrolizumab for selected patients with resectable NSCLC. Numerous studies on various targeted therapies and immunotherapy with or without chemotherapy are currently ongoing in the adjuvant setting. However, several questions regarding optimal strategies for adjuvant treatment remain unanswered. The present review summarizes the available literature, focusing on recent advances and ongoing trials with targeted therapy and immunotherapy in the adjuvant treatment of early-stage NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Carcinoma, Non-Small-Cell Lung | |
| 650 | 4 | |a Chemotherapy, Adjuvant | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Molecular Targeted Therapy | |
| 700 | 1 | |a Kim, Soo Han |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Min Ki |e verfasserin |4 aut | |
| 700 | 1 | |a Eom, Jung Seop |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberculosis and respiratory diseases |d 2012 |g 87(2024), 1 vom: 15. Jan., Seite 31-39 |w (DE-627)NLM222134194 |x 1738-3536 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2024 |g number:1 |g day:15 |g month:01 |g pages:31-39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4046/trd.2023.0085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2024 |e 1 |b 15 |c 01 |h 31-39 | ||